UK-US Pharma Deal: MPs Demand Transparency Over NHS Costs & ‘Trump Shakedown’ Claims
Growing controversy surrounds a recently finalized trade agreement between the UK and the United States concerning the cost of medicines. Critics allege the deal, reached with the previous US administration, represents a significant concession that could substantially increase healthcare costs for the UK’s National Health Service (NHS).
The Core of the Agreement
Under the terms of the agreement, the UK will increase its spending on new medicines, with a commitment to doubling expenditure from 0.3% to 0.6% of GDP by 2035. This increase is intended to secure tariff-free access for British pharmaceutical exports to the US market. In return, the UK is expected to allow for higher pricing of new drugs.
Concerns Over Cost
Several Members of Parliament (MPs) from across the political spectrum have voiced concerns that the deal could cost the UK government and the NHS billions of pounds annually by 2035. A cross-party group, including representatives from Labour, the Liberal Democrats, the Green Party, and the Scottish National Party, is actively seeking greater transparency regarding the agreement’s potential financial impact.
John McDonnell, who organized a meeting of concerned MPs, stated there are “real worries that the US/UK deal will result in significantly higher drug costs, which will in turn result in resources being drawn from the investment in NHS services.” He is calling for the publication of a comprehensive impact assessment.
Calls for Transparency
MPs are pressing Health Secretary Wes Streeting and Business and Trade Secretary Peter Kyle to release the government’s assessment of the deal’s effects. They are also considering a debate and vote in the Commons, as well as requesting inquiries from relevant select committees.
The Department of Health and Social Care (DHSC) and Science, Innovation and Technology Secretary Liz Kendall maintain the deal will result in an additional £1 billion in costs between 2025/26 and 2028/29. However, they have not provided estimates for costs beyond that period, nor have they specified which government department will be responsible for covering these expenses.
A Freedom of Information request submitted by Global Justice Now was denied, with the DHSC citing exemptions under freedom of information legislation. Tim Bierley of Global Justice Now questioned the secrecy, asking, “With all this secrecy, you have to wonder: what have ministers got to hide?”
Political Reactions
Liberal Democrat leader Ed Davey has strongly criticized the agreement, labeling it “a Trump shakedown of the NHS” and accusing the current government of “surrender” to the US. He argues that the deal allows a foreign regime to dictate NHS spending.
Frequently Asked Questions
What is the primary goal of the UK-US pharmaceutical deal?
The deal aims to safeguard UK patients’ access to medicines, boost pharmaceutical investment in Britain, and maintain tariff-free exports of UK drugs to the US.
What is the projected cost of the deal in the short term?
The DHSC estimates the deal will cost an extra £1 billion between 2025/26 and 2028/29.
What actions are MPs taking to address concerns about the deal?
MPs are seeking to compel the government to publish its impact assessment, considering a Commons debate and vote, and inviting select committees to investigate the deal’s origins and potential consequences.
As the agreement progresses, it remains to be seen whether further details regarding its long-term financial implications will be disclosed, and what impact it will ultimately have on the NHS budget and patient access to medicines.